Regenics shareholders as of October 1st  2017.

(minor deviations within source doscuments due to rounding of integers may apply)  

 

 

SHARES

%

Collas AS

189.500

3,2

Runhild Gammelsæter

94.200

1,6

Camilla Haglerød

22.000

0,4

Rune Nilsen

100.400

1,7

Life Capitol AS

2.344.800

39,6

Greyston Holding AS

117.700

2,0

Heldrup AS

1.827.200

30,9

Marcus Heldrup

101.100

1,7

Cornucopia AS

625.200

10,6

Intento AS

431.100

7,3

Gry Lønne Eriksson

650.00

1,1

 

 

 

SUM

5.918.200

100,00

 

Collas AS : Philippe Collas, Founder and Scientific Advisor

Runhild Gammelsæter: former CEO, private

Camilla Haglerød: former CEO, private

Rune Nilsen: private

Life Capitol AS: Jan Remmereit, founder

Greystone Holding AS: Jan Remmereit, founder

Heldrup AS: Tore Heldrup Rasmussen, Chairman Board

Markus Heldrup: Head of production, CPO, employee

Cornucopia AS: Henrik Lund, CEO, consultant

Inento AS: Christian Clemm, CMO, employee

Gry Lønne Eriksson:  Gry Lønne Eriksson, CSO, employee

 

Planned/completed share issues:

2015: Gross proceeds 1.0 mill NOK 

2016: Gross proceeds 1.72 mill NOK

2017: Gross proceeds 1.0 mill NOK (August)

(2017: Planned proceeds > 10 mill NOK at q2-q3 ),

Protocols (password required):

Annual Meeting 2015

Annual Meeting 2016

Ex. Ord. Annual Meeting 2016

Annual Meeting 2017

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.